Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?
Executive Summary
Pfizer's JAK inhibitor met its co-primary efficacy endpoints, but US FDA still wants discussion of lack of impact on radiographic progression.
You may also be interested in...
Historical Control In Psoriatic Arthritis May Hinge On Background Therapy
FDA says during meeting on Xeljanz application that it is interested in feedback on creating a control group for non-inferiority trials.
Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?
Arthritis Advisory Committee members say the company should bear some of the responsibility for managing the risk of shingles with the JAK inhibitor.
Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain
US advisory committee recommends approval of new indication for the JAK inhibitor but does not want any radiographic progression data in labeling amid questions about effect.